Characterized by the abysmal 18% five year survival chances, non-small cell lung
cancers (NSCLCs) claim more than half of their sufferers within the first year of being diagnosed.
Advances in biomedical engineering and molecular characterization have reduced the
NSCLC diagnosis via timid screening of altered gene expressions and impaired cellular responses.
While targeted chemotherapy remains a major option for NSCLCs complications, delayed
diagnosis, and concurrent multi-drug resistance remain potent hurdles in regaining normalcy,
ultimately resulting in relapse. Curcumin administration presents a benign resolve herein,
via simultaneous interception of distinctly expressed pathological markers through its pleiotropic
attributes and enhanced tumor cell internalization of chemotherapeutic drugs. Studies
on NSCLC cell lines and related xenograft models have revealed a consistent decline in tumor
progression owing to enhanced chemotherapeutics cellular internalization via co-delivery with
curcumin. This presents an optimum readiness for screening the corresponding effectiveness in
clinical subjects. Curcumin is delivered to NSCLC cells either (i) alone, (ii) in stoichiometrically
optimal combination with chemotherapeutic drugs, (iii) through nanocarriers, and (iv)
nanocarrier co-delivered curcumin and chemotherapeutic drugs. Nanocarriers protect the encapsulated
drug from accidental and non-specific spillage. A unanimous trait of all nanocarriers
is their moderate drug-interactions, whereby native structural expressions are not tampered.
With such insights, this article focuses on the implicit NSCLC curative mechanisms viz-a-viz,
free curcumin, nanocarrier delivered curcumin, curcumin + chemotherapeutic drug and
nanocarrier assisted curcumin + chemotherapeutic drug delivery.